kabutan

Heartseed Inc.(219A) Summary

219A
TSE Growth
Heartseed Inc.
1,872
JPY
-35
(-1.84%)
Mar 13, 3:30 pm JST
11.74
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
1,880.1
Mar 13, 11:21 pm JST
Summary Chart Historical News Financial Result
PER
PBR
5.95
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:03 am
1,860 JPY 11.69 USD
Previous Close Mar 12
1,907 JPY 11.99 USD
High Mar 13, 9:20 am
1,894 JPY 11.90 USD
Low Mar 13, 9:03 am
1,852 JPY 11.64 USD
Volume
271,100
Trading Value
0.51B JPY 3.18M USD
VWAP
1870.24 JPY 11.73 USD
Minimum Trading Value
187,200 JPY 1,174 USD
Market Cap
0.04T JPY 0.27B USD
Number of Trades
1,062
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
3,739
1-Year High Oct 2, 2025
50,688
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 844,900 1,670,900 1.98
Feb 27, 2026 816,200 1,743,400 2.14
Feb 20, 2026 802,900 1,820,800 2.27
Feb 13, 2026 729,100 1,773,400 2.43
Feb 6, 2026 880,000 1,765,000 2.01
Company Profile
Heartseed Inc. engages in the research and development of regenerative medicine products using iPS cells for cardiac regeneration.
Sector
Pharmaceuticals
Heartseed Inc. is a regenerative medicine venture originating from Keio University. The company is advancing the development of "cardiac regenerative medicine," a treatment method that involves transplanting micro-tissues (cardiac spheroids) derived from iPS cell-based cardiomyocytes into the heart, aiming to establish safety and efficacy. Heartseed possesses proprietary technologies, including techniques for producing high-purity cardiomyocytes and transplantation devices. With a vision for global expansion of cardiac regenerative medicine using allogeneic iPS cell-derived cardiac spheroids, the company entered into an exclusive worldwide technology partnership and licensing agreement with Novo Nordisk, a global pharmaceutical giant headquartered in Denmark, in May 2021.